Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Int J Cancer. 2017 May 26;141(4):711–720. doi: 10.1002/ijc.30782

Table 4.

Multivariate-adjusted odds ratios of developing cirrhosis, cirrhotic hepatocellular carcinoma (HCC) and non-cirrhotic HCC for serum aflatoxin B1 (AFB1)-albumin adducts levels among chronic hepatitis B virus carriers

AFB1-albumin adducts (fmol/mg) Multivariate-adjusted odds ratio (95% Confidence interval)
Cirrhosisa vs. controlb p-value Cirrhotic HCCa vs. cirrhosis onlyc p-value Cirrhotic HCCa vs. controlb p-value Non-cirrhotic HCCa vs. controld p-value
 Undetectable 1.00 (Referent) 1.00 (Referent) 1.00 (Referent) 1.00 (Referent)
 Low (<21.5) 1.47 (0.87–2.48) 0.15 2.20 (0.73–6.62) 0.16 2.53 (0.95–6.73) 0.06 2.38 (0.44–12.96) 0.3166
 High (≥21.5) 2.45 (1.51–3.98) 0.0003 3.04 (1.11–8.30) 0.0299 5.47 (2.20–13.63) 0.0003 5.39 (1.11–26.18) 0.0368
 (p-value for trend) 0.0001 0.0291 <0.0001 0.021
a

Cirrhosis and cirrhotic HCC developed in 9 years of follow-up and non-cirrhotic HCC developed in 4 years of follow-up.

b

Adjusted for other significant risk factors including age, gender, and serum alanine aminotransferase level.

c

Adjusted for other significant risk factors including age and gender.

d

Adjusted for other significant risk factors including age, gender, alcohol drinking and serum alanine aminotransferase level.